Denali Therapeutics Inc Cash Flow Reinvestment Rate
Denali Therapeutics Inc cash flow reinvestment rate. Denali Therapeutics Inc (DNLI) has a Cash Flow Reinvestment Rate of 0.71x as of December 2020, reinvesting $367.34 Million (capex $1.19 Million plus investments $-366.14 Million) from operating cash flow of $513.91 Million. Explore DNLI cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Denali Therapeutics Inc (2018–2020)
Cash flow reinvestment rate of Denali Therapeutics Inc from 2018 to 2020. Historical reinvestment intensity for Denali Therapeutics Inc across 2 annual periods. Explore DNLI capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Denali Therapeutics Inc Cash Flow Reinvestment Rate by Year (2018–2020)
Denali Therapeutics Inc cash flow reinvestment rate by year from 2018 to 2020. Year-by-year capital reinvestment analysis for Denali Therapeutics Inc. For the full cash flow conversion analysis, see Denali Therapeutics Inc cash conversion from operations.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2020 | 1.50x | $623.21 Million | $416.15 Million | $3.10 Million | ▼ -73.9% |
| 2018 | 5.74x | $287.42 Million | $50.12 Million | $3.39 Million | — |